PCVX - NASDAQ

Vaxcyte, Inc.

Vaxcyte, Inc.

PCVXยทNASDAQ

$46.93

-0.57%
HealthcareBiotechnology

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$6.78B
EPS-5.6300
P/E Ratio-8.19
Earnings Date08/05/2026
Vaxcyte, Inc.

Vaxcyte, Inc. Fair Value Envelope

PCVX ยท NASDAQ

Our analysis suggests that PCVX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $46.93, this represents a potential HIDDEN relative to our calculated worth for Vaxcyte, Inc..

HIDDEN
Intrinsic Value
Current Price: $46.93

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$794.1M
+ Cash & Equivalents$174.0M
Firm Value-$620.1M
- Debt$228.8M
Equity Value-$849.0M
/ Shares Outstanding130,904,923B
DCF Value-$6
OVERVALUED BY 114%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$387.5M
-$229.1M
-$135.4M
-$80.0M
-$47.3M
-$28.0M
-$16.5M
-$9.8M
-$5.8M
-$3.4M
Maintenance CapEx
-$1.6M
-$958.4K
-$566.5K
-$334.9K
-$198.0K
-$117.0K
-$69.2K
-$40.9K
-$24.2K
-$14.3K
Owner Earnings
-$389.2M
-$230.0M
-$136.0M
-$80.4M
-$47.5M
-$28.1M
-$16.6M
-$9.8M
-$5.8M
-$3.4M
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$360.3M
-$197.2M
-$107.9M
-$59.1M
-$32.3M
-$17.7M
-$9.7M
-$5.3M
-$2.9M
-$1.6M
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your PCVX research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.